Bogdan A Tigu

Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?

H. Einsele, C. Tomuleasa, Diana Gulei, 2022, Journal of Hematology & Oncology.

Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy

T. Ciuleanu, D. Cenariu, S. Pașca, 2021, Journal of cellular and molecular medicine.

An integrative model of cardiometabolic traits identifies two types of metabolic syndrome

L. Joosten, M. Netea, R. ter Horst, 2021, eLife.

Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma.

A. Ciechanover, H. Einsele, A. Buzoianu, 2023, Blood reviews.